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SUMMARY:  Potentially suboptimal antibiotic treatment was common in a national cohort of 
residents with urinary tract infections.  Predictors of suboptimal antibiotic treatment included 
prior fluoroquinolone exposure, chronic renal disease, and older age. These should be 





















BACKGROUND: Unnecessary antibiotic treatment of suspected urinary tract infection (UTI) 
is common in long-term care facilities (LTCFs). However, less is known about the extent of 
suboptimal treatment, in terms of antibiotic choice, dose, and duration, after the decision to 
use antibiotics has been made. 
METHODS: We described the frequency of potentially suboptimal treatment among 
residents with an incident UTI (first during the study with none in the year prior) in Veterans 
Affairs’ (VA) Community Living Centers (CLCs, 2013-2018). Time trends were analyzed 
using Joinpoint regression. Residents with UTIs receiving potentially suboptimal treatment 
were compared to those receiving optimal treatment to identify resident characteristics 
predictive of suboptimal antibiotic treatment, using multivariable unconditional logistic 
regression models. 
RESULTS: We identified 21,938 residents with an incident UTI treated in 120 VA CLCs, of 
which 96.0% were male.  Potentially suboptimal antibiotic treatment was identified in 65.0% 
of residents and decreased 1.8% annually (p<0.05). Potentially suboptimal initial drug choice 
was identified in 45.6% of residents, suboptimal dose frequency in 28.6%, and longer than 
recommended duration in 12.7%. Predictors of suboptimal antibiotic treatment included: prior 
fluoroquinolone exposure (adjusted odds ratio [aOR] 1.38), chronic renal disease (aOR 
1.19), age >85 years (aOR 1.17), prior skin infection (aOR 1.14), recent high white blood cell 
count (aOR 1.08), and genitourinary disorder (aOR 1.08). 
CONCLUSION: Similar to findings in non-VA facilities, potentially suboptimal treatment was 
common but improving in CLC residents with an incident UTI. Predictors of suboptimal 
antibiotic treatment should be targeted with antibiotic stewardship interventions to improve 
UTI treatment.  
KEYWORDS: urinary tract infection; suboptimal antibiotic treatment; Veterans Affairs; 





















Inappropriate antibiotic use has become a major public health threat due to the widespread 
emergence of antibiotic resistant bacteria.  In long-term care facilities (LTCFs), antibiotics 
are among the most commonly used medications with between 47-79% of residents 
receiving one or more antibiotics each year.1 It has been estimated that up to 75% of 
antibiotic use in LTCFs is inappropriate.2  
 
Suspected urinary tract infection (UTI) is the most common indication for antibiotics and 
drives inappropriate antibiotic treatment in LTCFs. Approximately, 32% of the antibiotics 
given to residents are for UTIs and between 25-85% of antibiotic prescriptions for UTIs 
among residents are inappropriate.3-6 Inappropriate antibiotic treatment for UTI may include 
unnecessary use when an antibiotic is not indicated or suboptimal use based on antibiotic 
drug choice, dose, and/or duration of treatment. Unnecessary treatment of asymptomatic 
bacteriuria is among the greatest contributors to inappropriate antibiotic use in LTCFs.1 
Suboptimal antibiotic treatment is also common, however previous work in this area has 
largely focused on unnecessary UTI treatment without evaluating suboptimal antibiotic 
treatment.3,5,6 Prior assessments of suboptimal antibiotic drug choice, dose, and duration 
among residents in LTCFs are limited.4,6,7  
 
Large-scale evaluations of suboptimal antibiotic treatment and type of suboptimal treatment 
in LTCFs are necessary to identify target areas for improvement. The aims of this work were 
to define potentially suboptimal antibiotic treatment, as assessed from drug choice, dose 
frequency, and duration, among residents with an incident UTI treated in Veterans Affairs’ 



















predictors of potentially suboptimal antibiotic treatment. Though unnecessary antibiotic 
treatment is also a major problem in LTCFs, our study focused on suboptimal antibiotic 
treatment which could be improved with regards to the choice of drug, dose frequency, and 
duration used after the decision to use antibiotics had been made.8 
 
METHODS 
Study design, setting, and population. 
We conducted a retrospective cohort study among adult (age >18 years) residents in VA 
long-term care units, called CLCs with a suspected UTI between January 2013 and 
December 2018. UTIs required collection of a urine culture and an antibiotic given on the 
culture collection date or within 3 days after culture collection.9 We based our definition of 
UTI on Infectious Diseases Society of America (IDSA) guidelines which require detection of 
bacteriuria (in addition to symptoms) for UTI diagnosis.10,11 When a UTI is suspected, 
providers frequently obtain a urine culture before treatment is started, but often do not adjust 
treatment based on urine culture results.12 As such, a suspected UTI required collection of a 
urine culture, regardless of whether the microbiology results were ultimately positive or 
negative for bacterial growth. For each UTI, the antibiotic treatment period was defined as 
the interval of antibiotic therapy from the start to the end of treatment, identified by gaps of 2 
or more consecutive days in antibiotic treatment.13 All urine cultures collected during the UTI 
treatment period were considered to be for the same UTI. We included only residents with 
an incident CLC UTI, defined as the first during the study period with no UTIs treated in a 
CLC in the year prior.  
 
Residents with suspected UTIs could have had culture-negative or culture-positive urine 



















number of organisms identified and the organisms identified.14 Residents with UTIs could 
have had a UTI diagnosis during the UTI treatment period, identified using International 
Classification of Diseases (ICD), 9th or 10th Revision diagnosis codes, but this was not a 
requirement for inclusion.15 
 
IDSA guidelines recommend treatment of asymptomatic bacteriuria, a condition distinct from 
UTI, only in the presence of pregnancy or planned urologic procedure.11 We thus excluded 
female residents of child bearing age and residents with a urologic procedure within 2 weeks 
of the index date.9 We excluded residents with a UTI associated with chronic antibiotic 
treatment (>30 days).16 To avoid capturing treatment of another potential infection, we 
excluded residents with a positive culture from another source during the UTI treatment 
period, unless it was a blood culture growing the same organism/s as in the urine.9 We 
excluded residents in which any non-UTI or uncommon antibiotics were used (defined in 
Figure 1).  
 
Data sources. 
This study included data from the national VA Corporate Data Warehouse and the Minimum 
Data Set (MDS). VA data used included: microbiology, inpatient and outpatient care, 
diagnoses, procedures, surgeries, demographics, vital status, inpatient and outpatient 
medications, laboratory, and vital measurements including temperature. We obtained urine 
culture data from microbiology data and medications from barcode medication administration 























In Table 2, we present detailed definitions for potentially suboptimal antibiotic treatment. We 
defined potentially suboptimal antibiotic treatment based on exposure to any subtype of 
suboptimal initial drug choice, dose frequency, and/or duration. We considered an initial drug 
choice to be potentially suboptimal based on evidence of resistance to that agent 
considering the resident’s previous urine culture and susceptibility (C&S) results in the 
previous 180-days.17  If no previous urine 180-day C&S were available, we assessed for 
insufficient coverage (described in Table 2) with the agents used considering the local CLC-
urinary antibiogram for the year prior.17 As previously described in prior work, we created 
annual urine antibiograms for every CLC according to Clinical and Laboratory Standards 
Institute (CLSI) recommendations of using the first clinical isolate cultured per patient per 
bacterial species.18,19 We considered dose frequency to be potentially suboptimal if it was 
not in accordance with recommendations for dosing based on renal function.4  We 
considered duration to be potentially suboptimal if treatment duration was longer than expert 
recommendations, defined as greater than 14 days.16,20  We also identified de-escalation of 
antibiotic therapy among the study population. We assessed rates of de-escalation of 
antibiotic therapy from initial broad-spectrum coverage to targeted, narrow-spectrum 
coverage by day 4 (defined in Table 2).21,22  The antibiotic spectrum index (ASI) was used to 
determine antibiotic spectrum, where the antibiotics used were assigned a score from 1 





















Potential predictors.  
We evaluated baseline resident characteristics as potential independent predictors of 
potentially suboptimal antibiotic treatment. Potential predictors were based on clinical 
relevance and/or previous work and selected a priori.23-26 Resident characteristics assessed 
included socio-demographics, comorbidities, comorbidity burden, prior healthcare 
exposures, prior infections, prior antibiotic exposures, prior positive cultures, prior urine 
culture collection, and prior laboratory results.  
 
Analytic approach. 
We quantified the frequency of potentially suboptimal antibiotic treatment, subtypes of 
potentially suboptimal treatment, and de-escalation among our study population of CLC 
residents with an incident UTI. Stratified results were assessed by urine culture results 
(positive or negative) and presence or absence of a current UTI diagnosis during antibiotic 
treatment. Time trends were analyzed using Joinpoint regression.  Joinpoint regression 
software was used to calculate average annual percent changes (AAPC) and 95% 
confidence intervals (CI) for the frequency of potentially suboptimal antibiotic treatment over 
the study period. 
 
We compared resident characteristics between residents receiving potentially suboptimal 
and optimal antibiotic treatment. Differences in resident characteristics between groups were 
analyzed using chi-square for categorical data and Student’s t test or the Wilcoxon rank sum 




















We used backwards, manual, stepwise unconditional logistic regression to identify resident 
characteristics that were predictors of potentially suboptimal antibiotic treatment.27 We 
included variables with a p-value of <0.10 from univariate analysis in subsequent 
multivariable analysis. We removed variables one-by-one from the multivariable model until 
remaining variables in the final model demonstrated statistical significance (p-value <0.05).27 
We checked variables in the final model for tolerance and variance inflation. Variables in the 
final model demonstrated tolerance above 0.1 and variance inflation below 2, indicating 
absence of collinearity between predictors.27 We used the final multivariable logistic 
regression model to calculate adjusted odds ratios (aOR) and 95% CI. Sensitivity analyses 
were conducted to determine whether predictors varied by subtype of potentially suboptimal 
antibiotic treatment (drug choice, dose frequency, and longer than recommended duration). 
 
RESULTS 
We identified 21,938 CLC residents from 120 VA CLCs with an incident UTI after applying all 
inclusion and exclusion criteria (Figure 1). The median resident age was 74 years 
(interquartile range [IQR] 67-85) and 96.0% were male. Positive cultures with one organism 
(51.0%) or two or more organisms (15.2%) were common, and 33.8% were culture negative 
(Table 1). Initial antibiotic treatment with fluoroquinolones (36.2%), cephalosporins (27.6%), 
and typical genitourinary tract agents (20.8%) were common (supplemental Table 1). 
 
Potentially suboptimal antibiotic treatment was identified in 65.0% (n=14,267) of residents 
(Table 3).  Potentially suboptimal antibiotic treatment decreased by 1.8% (95% CI -2.8% – -
0.7%) per year (see Supplementary Figure 1). A potentially suboptimal initial drug choice 
was identified in 45.6% (n=10,012) of residents, suboptimal dose frequency in 28.6% 
(n=6,272), and longer than recommended duration in 12.7% (n=2,787). Antibiotics were not 



















culture result and presence or absence of a current UTI diagnosis (Table 3) and by initial 
antibiotic treatment class (supplemental Table 2). 
 
A larger proportion of the group that received potentially suboptimal antibiotic treatment were 
in the oldest age group (age > 85 years: 26.9% vs 24.0%, p<0.001); had chronic renal 
disease (30.2% vs 28.1%, p=0.002); and had prior fluoroquinolone exposure (15.4% vs 
11.6%, p<0.001,Table 4). 
 
We identified the following 6 resident characteristics that were predictive of potentially 
suboptimal antibiotic treatment in CLC residents with UTI (Table 5): fluoroquinolone 
exposure in previous 30 days (aOR 1.38), comorbid chronic renal disease (aOR 1.19), age 
>85 years (aOR 1.17), skin or soft tissue infection in the previous year (aOR 1.14), recent 
high white blood cell count (WBC; aOR 1.08), and comorbid genitourinary disorder (aOR 
1.08). 
 
Results of sensitivity analyses can be found in the supplemental material (Supplementary 
Table 3). For suboptimal drug choice, prior fluoroquinolone exposure and age >85 years 
remained significant predictors.  For suboptimal dose frequency, prior fluoroquinolone 
exposure, comorbid chronic renal disease, age > 85 years, and recent high WBC remained 
significant predictors. For longer than recommended duration, prior skin or soft tissue 






















In this retrospective cohort study of 21,938 CLC residents with an incident UTI treated in 120 
VA CLCs nationally, 65.0% of residents received potentially suboptimal antibiotic treatment 
but was decreasing over the study period. Improvements in suboptimal antibiotic treatment 
over the study period are likely related to increased antibiotic stewardship efforts among VA 
facilities nationally, such as a mandate for VA facilities to implement and maintain antibiotic 
stewardship programs since January 2014.28   
 
The lack of a standard definition for suboptimal antibiotic treatment and subtypes of 
potentially suboptimal treatment hinders comparisons between studies.3 One previous study 
evaluated the frequency of subtypes of potentially suboptimal antibiotic treatment among 
residents with UTI treated in two non-VA community-based nursing homes in Rhode Island.4 
We found a lower frequency of potentially suboptimal drug choice (46% vs 72%), drug 
dosing frequency based on creatine clearance (29% vs 46%), and an overly long duration 
(13% vs 67%) as compared to the previous work, likely due to differing suboptimal treatment 
definitions and study populations.4 As clinical treatment guidelines for complicated UTIs in 
older adults, in particular males, have not been developed, definitions of appropriate 
antibiotic treatment are adapted from expert opinion and IDSA treatment guidelines for 
uncomplicated UTI in women.16,17,29  
 
Further, 78% of the other study population was female, as compared with our largely male 
(96%) study population.4 UTIs in males are generally considered complicated and 
fluoroquinolones are often considered first-line in men with severe UTI symptoms or concern 
for prostate involvement.20 In women with uncomplicated cystitis, empiric use of 
fluoroquinolones is generally not recommended first-line due to an increased risk for 



















agents.17,30  Initial fluoroquinolone use was not considered suboptimal in our study, but in 
previous work among the largely female non-VA nursing home population, empiric 
fluoroquinolone use was the most common reason for suboptimal drug choice.4 
Fluoroquinolones were the most common initial antibiotic treatment in our study (36.2%).  
The frequency of potentially suboptimal drug choice would have been higher had we defined 
fluoroquinolone use as suboptimal.  
 
There are differences in recommended treatment durations between male and female study 
populations. Durations as short as 3 days are recommended in females with uncomplicated 
UTIs.17 The optimal duration of treatment for men is less well studied, however longer 
durations between 7-14 days are generally recommended.16,20 The prior study among a 
largely female (78%) non-VA nursing home population found that 64% of antibiotics were 
continued too long, which was defined as over 3 days in female residents, except for those 
treated with nitrofurantoin in which over 7 days was deemed too long, and over 14 days in 
male residents.4  As our study was among mostly males, we defined suboptimal duration as 
over 14 days.  Interestingly, the average duration of treatment was similar in both our study 
and the prior study at about 8 days and had we used a more stringent definition of 7 days to 
be suboptimal, the frequency of suboptimal duration in our study would have increased to 
68.4%.  
 
The strongest predictor of potentially suboptimal antibiotic treatment was prior 
fluoroquinolone exposure. Our finding may be related to “prescribing tendencies” for use of 
suboptimal antibiotics. Previous work among 1,695 long-term care physicians demonstrated 
that a prescriber’s tendency to select fluoroquinolone antibiotics and to select prolonged 



















year.31 It is plausible that residents were treated by CLC prescribers that used 
fluoroquinolones as a suboptimal UTI drug choice repeatedly.  
 
We found that a recent high WBC and age >85 years were also predictive of potentially 
suboptimal UTI treatment. These findings may be related to differences in the way UTIs are 
treated when there is concern for more severe infection with systemic involvement, 
particularly among older patients. Prescribers, for example, may not dose adjust for renal 
impairment in the presence of severe UTIs. In older patients, prescribers may prefer certain 
antibiotics or alternative durations compared with younger patients. A prospective audit and 
feedback approach where a clinical pharmacist or infectious diseases expert reviews 
antibiotic treatments and tailors the drug choice, dose frequency, and duration of each UTI 
episode may be most helpful among older residents and those with severe disease, to 
improve antibiotic treatment. Older residents may also be more likely to receive suboptimal 
antibiotics due to inappropriate dose adjustments for renal dysfunction. As expected, we 
found that chronic renal disease remained a significant predictor of suboptimal dose 
frequency, as drugs are commonly dosed incorrectly in residents with renal dysfunction. As 
such, renal dose adjustment protocols and guidance for older residents may improve 
treatment. The VA is a national leader in antibiotic stewardship, and antibiotic stewardship 
activities such as these have already been implemented in many VAs and may explain the 
trend in improving antibiotic treatment we observed over the study period.28,32 
 
Interestingly, we found several characteristics that were protective against potentially 
suboptimal antibiotic treatment. These factors included a UTI diagnosis in the year prior, 
urine cultures in the year prior, and hospitalization in the 30 days prior. This suggests that 
residents were more likely to receive optimal antibiotic treatment if they had a prior UTI in 



















any setting. The empiric treatment of residents with UTIs without any prior microbiology 
results or without any previous UTI treatment to guide current treatment is challenging, and 
continued work should investigate novel strategies to improve treatment in these residents.  
 
We acknowledge the limitations of this retrospective study. We included only residents with a 
first UTI in which a urine culture was obtained and that was treated with antibiotics in a VA 
CLC. Suboptimal treatment may be higher or lower in subsequent UTIs. Accurately defining 
UTIs in long-term care residents can be challenging, and despite requiring the presence of a 
urine culture and antibiotic treatment, we may have included residents with colonization that 
were not true symptomatic UTIs (33.8% culture negative, 75.4% without diagnosis) but were 
still treated with antibiotics. Additionally, the antibiotic treatment we captured may have been 
for another infection type. Older adults can often have muddled clinical findings upon 
presentation prompting a “treat with the kitchen sink” approach in order to cover respiratory 
and urinary pathogens. However, our results were similar when stratified by UTI diagnosis 
and urine culture results, which suggests the antibiotic treatment captured was likely for a 
suspected UTI. Additionally, sometimes providers only obtain a urinary dipstick and/or 
urinalysis without a urine culture when they suspect a UTI. We did not capture dipstick or 
urinalysis results, and as such our study population did not include residents treated for UTI 
without urine cultures. There are limitations with our definition of potentially suboptimal 
antibiotic treatment. No established definitions for potentially suboptimal antibiotic treatment 
or each subtype of suboptimal treatment have been developed and thus we made 
assumptions for what constitutes suboptimal antibiotic treatment based on available 
guidelines and expert opinion.17 We described the frequency of de-escalation in all residents, 
and did not assess the necessity of de-escalation. Our predictive analysis is limited by the 
variables included in the model. We were unable to capture urinary catheter use in our 
population which may predict suboptimal treatment. The generalizability of findings to non-




















In this large national study of 21,938 CLC residents with an incident UTI treated in 120 VA 
CLCs, potentially suboptimal antibiotic treatment was common but improving. We defined 
and described several subtypes of potentially suboptimal treatment, including drug choice, 
dose frequency, and longer than recommended duration. Several resident predictors of 
potentially suboptimal treatment were identified. These may be important targets for 
antibiotic stewardship intervention to further improve the treatment of UTI in VA CLCs 
nationally and warrant future research. Targeted areas for antibiotic stewardship activities in 
VA CLCs should be in residents with UTIs who have had prior fluroquinolone exposure, 
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Table 1.  Characteristics of urine cultures collected among residents with an incident 
urinary tract infection treated in VA Community Living Centers.   
Microbiology characteristic  Number (%) 
Urine culture results  
        Culture-negative 7,413 (33.8) 
        Culture-positive (single organism) 11,190 (51.0) 
        Culture-positive (> two organisms)* 3,335 (15.2) 
Organism exposure  
Gram-negatives**  
        Escherichia coli   3,928 (17.9) 
        Proteus mirabilis      2,466 (11.2) 
        Klebsiella spp. 2,209 (10.1) 
        Pseudomonas aeruginosa        1,206 (5.5) 
        Enterobacter spp. 501 (2.3) 
        Citrobacter spp. 330 (1.5) 
        Providencia spp. 283 (1.3) 
        Morganella morganii 197 (<1) 
Gram-positives  
        Enterococcus spp. 1906 (8.7) 
        Staphylococcus aureus       567 (2.6) 
Other organisms 3,088 (14.1) 
CLC= Community Living Center, spp.=species, UTI=Urinary tract infection, VA=Veterans 
Affairs 




















Characteristics of urine microbiology cultures are presented for 21,938 CLC residents with 
an incident UTI between 2013 to 2018.  
 
 
Culture results were considered culture-negative if no growth was identified from any of the 
urine cultures collected during the UTI treatment period. 
 
Culture results were considered culture-positive if growth was identified from any of the urine 
cultures collected during the UTI treatment period with no minimum organism quantitative 
count. No minimum urine quantitative counts were required for culture-positive UTIs, as 
previous work has shown that minimum quantitative thresholds may not be appropriate to 
detect all UTIs and infection is likely to occur at lower quantitative levels in certain patients 
including those with catheters or chronic kidney disease.33,34 
 
Potentially suboptimal antibiotic treatment was measured in the same manner for both 
positive and negative cultures (see Table 2). 
 
*Most positive cultures with growth of two or more organisms only grew two organisms 
(n=2,878, 86.3%). 
 



















Table 2. Study definitions used to measure potentially suboptimal antibiotic treatment, subtypes of potentially suboptimal antibiotic 
treatment and antibiotic de-escalation among residents with an incident urinary tract infection treated in VA Community Living Centers.   





Use of a potentially suboptimal: 
1) antibiotic drug choice;  
2) antibiotic dose frequency;  
and/or 
3) antibiotic treatment duration. 





Use of a suboptimal initial antibiotic drug 
choice on day 1 based on: 1) evidence of 
resistance to that agent considering the 
resident’s urine culture and susceptibly 
(C&S) results from the previous 180 days, 
or otherwise 2) the local CLC antibiogram 
(if no previous urine culture and susceptibly 
results). 
First, if previous urine C&S results 
were available in the previous 180-
days, defined as administration of 
antibiotic despite previous resistance 
to that agent. 
 
Otherwise, if no previous urine C&S 
results were available in the previous 
180-days, defined as administration 
of only antibiotics with insufficient 
coverage considering the local CLC-
Defined suboptimal drug choice based on 
resident’s previous urine C&S, as previous 
microbiology data are highly predictive of 
current antibiotic susceptibly and it is 
recommended that previous urine C&S guide 
initial empiric treatment when available.35,36  
 
When previous cultures not available, local 
antibiograms or facility-level antibiotic 
susceptibility reports should guide therapy.35 


















urinary antibiogram for the year 
prior.17**  
 
Insufficient coverage was defined as 
percent susceptibility less than 
80%.17 
be avoided as initial empiric therapy for UTI 
when facility resistance rates for the most 
common organisms causing UTI exceed 10 






Use of a suboptimal antibiotic dose 
frequency based on renal function. 
 
Renal function was estimated using 
the Cockcroft–Gault equation using 
the most recent serum creatine 
within the 365 days prior. 
 
Assessed if the average number of 
doses per day were concordant with 
recommended dosage based on 
renal function.4 
 
If the number of doses administered 
per day were not available, dose 
frequency was estimated by diving 
We based definitions on antibiotic dosing 
guidelines for adult patients based on renal 
function (estimated using Cockcroft–Gault). 
 
Dose frequency could have been suboptimal 




















the quantity dispensed by the days’ 
supply. 
 
If renal function could not be 
estimated due to missing serum 
creatine, dose frequency was 
defined as suboptimal, as without an 
estimate of renal function, clinicians 






Use of a longer than recommended 
antibiotic treatment duration. 
 
A excessive duration was defined as 
a duration greater than 14 days. 
We used a generous definition as a duration 
up to 14 days is recommended for patients 
with complicated UTI.16,20 While shorter 
treatment durations of 7 days or less are 
recommended for women with uncomplicated 
cystitis and may even be appropriate for men 
with non-severe disease and no complicating 
conditions, UTIs in males are generally 


















to 14 days of therapy.17 
    
De-escalation Use of antibiotics with a lower antibiotic 
spectrum on day 4 of the treatment period 
as compared to day 1.22 
The antibiotic spectrum index (ASI) 
used to determine the antibiotic 
spectrum on days 1 and 4.22 
 
ASI scores used to rank each 
antibiotic used from 1 for the most 
narrow spectrum agents to 13 for the 
most broad spectrum agents.22  
 
De-escalation events identified by 
subtracting the day 4 ASI from the 
day 1.21  
 
De-escalation was defined as a 
positive change in score.21  
ASI is a score that was developed to classify 
commonly used antibiotics based on their 
spectrum of activity.22  


















**We created annual antibiograms for every CLC facility according to Clinical and Laboratory Standards Institute (CLSI) recommendations of using 
the first clinical isolate cultured per patient per bacterial species.18,19 Individual antibiotics were grouped into antibiotic classes and an overall percent 
susceptibility was determined considering the most common urinary gram-negative organisms (Escherichia coli, Proteus mirabilis, and Klebsiella 



















Table 3.  Frequency of potentially suboptimal antibiotic treatment, subtype of potentially suboptimal antibiotic treatment and antibiotic 
de-escalation among residents with an incident urinary tract infection treated in VA Community Living Centers. 
 Total Urine Culture Resulta UTI Diagnosisb 
 
21,938 
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suboptimal 
3,914/ 


























subtypes  (27.4) (30.7) (26.3) 



















    
 
 
      Drug 
choice** 
10,012 
(45.6) 4,029 (54.4) 4,624 (41.3) 1,359 (40.7) 
2,393 
(44.2) 7,619 (46.1) 
      Dose 
frequency*** 
6,272 
(28.6) 2,092 (28.2) 3,174 (28.4) 1,006 (30.2) 
1,842 
(34.1) 4,430 (26.8) 
      
Duration**** 
2,787 
(12.7) 778 (10.5) 1,415 (12.6) 594 (17.8) 935 (17.3) 1,852 (11.2) 
        - 
Duration in 
days (median, 
interquartile 8 (5-11) 



















        - 
Duration > 7 
days 
14,998 





        - 
Duration > 10 
days 
7,939 
(36.2) 1,956 (26.4) 4,436 (39.6) 1,547 (46.4) 
2,505 
(46.3) 5,434 (32.9) 
No antibiotic 
de-escalation 
by day 4****** 
16,239 





CLC= Community Living Center, UTI=urinary tract infection, VA=Veterans Affairs 
Data are n (%) unless otherwise specified.  
 
Frequency of potentially suboptimal antibiotic treatment, subtypes of potentially suboptimal antibiotic treatment and antibiotic de-escalation are 
presented for 21,938 CLC residents with an incident UTI between 2013 to 2018 overall, by urine culture result; and by presence or absence of a 



















aCulture results were considered culture-negative if no growth was identified from any of the urine cultures collected during the UTI treatment 
period. Culture results were considered culture-positive if growth was identified from any of the urine cultures collected during the UTI treatment 
period with no minimum organism quantitative count. 
 
bA current UTI diagnosis required a UTI diagnosis during the UTI treatment period. 
 
*Potentially suboptimal antibiotic treatment was defined as exposure to any of subtype of potentially suboptimal antibiotic treatment (drug, dose 
frequency dose frequency, and/or duration). 
 
**Potentially suboptimal initial drug choice was defined based on previous urine cultures and susceptibilities or local CLC urine antibiogram. Initial 
treatment was defined as antibiotics given on the first day of the UTI treatment period. 
 
***Potentially suboptimal dose frequency was defined based on renal function.  
 



















******De-escalation was defined as use of antibiotics with a lower antibiotic spectrum on day 4 as compared to day 1. We presented the percent of 
residents with a UTI episodes not de-escalated by day 4. All residents were assessed for de-escalation, regardless of the necessity of de-




















Table 4.  Comparison of baseline characteristics for residents with incident UTIs receiving potentially 
suboptimal antibiotic treatment versus optimal antibiotic treatment. 








Age   <0.001 
   < 65 years 2,405 (16.9) 1,334 (17.4)  
   65-74 years 4,606 (32.3) 2,669 (34.8)  
   75-84 years 3,414 (23.9) 1,825 (23.8)  
   > 85 years 3,842 (26.9) 1,843 (24.0)  
Male gender 13,701 (96.0) 7,356 (95.9) 0.617 
White race 10,670 (74.8) 5,799 (75.6) 0.187 
Married 5,896 (41.3) 3,188 (41.6) 0.738 
Hispanic ethnicity 633 (4.4) 309 (4.0) 0.155 
Comorbidities*    
    Hypertension 10,833 (75.9) 5,912 (77.1) 0.058 
   Cardiopulmonary disease 10,298 (72.2) 5,675 (74.0) 0.004 
    Genitourinary disorder 7,568 (53) 4,215 (54.9) 0.007 
    Diabetes   6,883 (48.2) 3,688 (48.1) 0.813 
    Gastrointestinal/ nutritional disorder  6,260 (43.9) 3,428 (44.7) 0.249 
    Atherosclerosis 5,597 (39.2) 3,016 (39.3) 0.900 
    Benign prostatic hyperplasia 5,012 (35.1) 2,788 (36.3) 0.073 
   Rheumatic disease 5,012 (35.1) 2,726 (35.5) 0.548 
    Chronic renal disease 4,305 (30.2) 2,159 (28.1) 0.002 
    Cancer   4,074 (28.6) 2,259 (29.4) 0.164 



















    Dementia 3,185 (22.3) 1,725 (22.5) 0.782 
    Obesity 2,526 (17.7) 1,438 (18.7) 0.056 
    Parkinson’s disease 972 (6.8) 520 (6.8) 0.924 
   Liver disease  925 (6.5) 520 (6.8) 0.401 
Previous infections and other diagnoses*    
    Urinary tract infection  4,903 (34.4) 3,119 (40.7) <0.001 
   Acute respiratory failure 4,221 (29.6) 2,326 (30.3) 0.256 
   Pneumonia 3,148 (22.1) 1,674 (21.8) 0.679 
   Skin or soft tissue infection 2,936 (20.6) 1,456 (19.0) 0.005 
   Complication of surgery or medical care 2,170 (15.2) 1,269 (16.5) 0.010 
   Complication of device, implant or graft  1,734 (12.2) 984 (12.8) 0.149 
   Fever 1,380 (9.7) 784 (10.2) 0.195 
   Adverse effect of medical care  1,192 (8.4) 659 (8.6) 0.549 
   Adverse effect of drug  1,139 (8.0) 692 (9.0) 0.008 
    Fracture of the hip 809 (5.7) 475 (6.2) 0.117 
   Shock 696 (4.9) 408 (5.3) 0.155 
   Bronchitis  520 (3.6) 297 (3.9) 0.397 
Elixhauser score at or above the median 7,845 (55.0) 4,321 (56.3) 0.057 
Cognitive function**    0.002 
   Severely impaired 992 (7.0) 523 (6.8)  
   Moderately impaired 2,300 (16.1) 1,185 (15.4)  
   Mildly impaired 3,161 (22.2) 1,803 (23.5)  
   Cognitively intact 5,591 (39.2) 3,094 (40.3)  
   Unknown 2,223 (15.6) 1,066 (13.9)  
Severe functional limitation (ADL > 23)*** 1,909 (13.4) 1,005 (13.1) 0.561 



















    Time since admission to UTI in days 
(median, interquartile range) 28 (8.0 - 118.0) 29 (9.0 - 102.0) 0.923 
    Hospitalization, 30 days prior treatment 4,279 (30.0) 2,400 (31.3) 0.047 
    Intensive care unit, 30 days prior treatment 1,052 (7.4) 599 (7.8) 0.244 
    Surgery, 30 days prior treatment 960 (6.7) 506 (6.6) 0.708 
Previous antibiotic exposures    
    Any antibiotic, 30 days prior to treatment 6,570 (46.1) 3,358 (43.8) 0.001 
    Fluoroquinolone, 30 days prior to treatment 2,192 (15.4) 893 (11.6) <0.001 
Previous resistant urine cultures, 30 days 
prior to treatment**** 
   
      Fluoroquinolone resistant Pseudomonas 
aeruginosa, Klebsiella spp., Escherichia coli, or 
Enterobacter spp. 777 (5.4) 543 (7.1) <0.001 
      Extended spectrum cephalosporin resistant 
Klebsiella spp., Escherichia coli, or 
Enterobacter spp. 467 (3.3) 345 (4.5) <0.001 
      Aminoglycoside resistant Pseudomonas 
aeruginosa, Klebsiella spp., Escherichia coli, or 
Enterobacter spp. 348 (2.4) 258 (3.4) <0.001 
      Piperacillin-tazobactam resistant 
Pseudomonas aeruginosa, Klebsiella spp., 
Escherichia coli, or Enterobacter spp. 306 (2.1) 228 (3) <0.001 
      Multidrug resistant Pseudomonas 
aeruginosa, Klebsiella spp., Escherichia coli, or 
Enterobacter spp. 290 (2.0) 174 (2.3) 0.247 



















aeruginosa, Klebsiella spp., Escherichia coli, or 
Enterobacter spp. 
      Methicillin-resistant Staphylococcus aureus     122 (0.9) 109 (1.4) <0.001 
      Vancomycin-resistant Enterococcus spp. 108 (0.8) 64 (0.8) 0.536 
Previous resistant non-urine cultures, 30 
days prior to treatment**** 
   
      Fluoroquinolone resistant Pseudomonas 
aeruginosa, Klebsiella spp., Escherichia coli, or 
Enterobacter spp. 131 (0.9) 83 (1.1) 0.239 
      Extended spectrum cephalosporin resistant 
Klebsiella spp., Escherichia coli, or 
Enterobacter spp. 97 (0.7) 65 (0.8) 0.167 
      Aminoglycoside resistant Pseudomonas 
aeruginosa, Klebsiella spp., Escherichia coli, or 
Enterobacter spp. 75 (0.5) 40 (0.5) 0.967 
      Piperacillin-tazobactam resistant 
Pseudomonas aeruginosa, Klebsiella spp., 
Escherichia coli, or Enterobacter spp. 77 (0.5) 44 (0.6) 0.747 
      Multidrug resistant Pseudomonas 
aeruginosa, Klebsiella spp., Escherichia coli, or 
Enterobacter spp. 59 (0.4) 39 (0.5) 0.315 
      Carbapenem resistant Pseudomonas 
aeruginosa, Klebsiella spp., Escherichia coli, or 
Enterobacter spp. 187 (1.3) 122 (1.6) 0.094 
      Methicillin-resistant Staphylococcus aureus     219 (1.5) 103 (1.3) 0.259 



















Previous urine culture collection, year prior 
to treatment***** 
   
      Outpatient urine culture  9,443 (66.2) 6,222 (81.1) <0.001 
      CLC urine culture 6,419 (45) 5,004 (65.2) <0.001 
      VAMC urine culture 5,367 (37.6) 3,413 (44.5) <0.001 
Previous laboratory results    
      Recent high WBC (> 10 x 103/μL, within 7 
days prior to treatment)****** 4,386 (30.7) 2,173 (28.3) <0.001 
      Recent high temperature (> 100.0 degrees 
F, within 7 days prior to treatment) ******* 297 (2.1) 123 (1.6) 0.014 
 CLC= Community Living Center; UTI= Urinary tract infection; VA= Veterans Affairs; VAMC= Veterans Affairs 
Medical Center; WBC= White blood cell count 
      
Data are presented as the number and percent, unless otherwise indicated. 
 
Characteristics of residents are presented for 21,938 CLC residents with an incident UTI treated between 2013 
to 2018. 
 
We compared CLC residents with an incident UTI receiving potentially suboptimal antibiotic treatment and 
those receiving potentially optimal antibiotic treatment.  Potentially suboptimal antibiotic treatment was defined 
as exposure to any subtype of potentially suboptimal antibiotic treatment: drug choice (based on previous urine 
cultures and susceptibilities or local CLC urine antibiogram), dose frequency (based on renal function), and/or 




















*Comorbidities and prior infections were identified using ICD-9 or 10 diagnosis and procedure codes within one 
year prior to the UTI. The Clinical Classifications Software of the Agency for Healthcare Research and Quality 
categorizations were used to group specific diagnoses and procedures into comorbid conditions and infection 
type and used to calculate the Elixhauser score.15  
 
**Prior antibiotic exposures (fluoroquinolones and/or any other antibiotic) and positive cultures (E. coli, 
Klebsiella spp., Enterobacter, and P. aeruginosa antibiotic resistant phenotypes, methicillin-resistant 
Staphylococcus aureus (MRSA), and vancomycin resistant Enterococcus spp. (VRE) as defined by the 
Centers for Disease Control and Prevention [CDC]) were assessed in the 30 days prior to the first day of 
treatment.37 
 
***Cognitive function was defined using the MDS 3.0 Cognitive Function Scale (CFS).38 
 
****Physical functional status was dichotomized into severe functional limitation based on an activities of daily 
living score (ADL) > 23 and non-severe functional limitation (ADL < 23).39 
 
*****Prior positive urine cultures were assessed separately from all other positive culture types. 
 
***** Prior urine culture collection (positive or negative) in the CLC, VAMC, or outpatient settings were 




















******Recent high WBC was defined as a WBC > 10 x 103/μL within 7 days prior to treatment as compared to a 
measurement below or missing. 
 
*******Recent high temperature > 100.0 degrees within 7 days prior to treatment as compared to a 





















Table 5. Resident characteristics identified as independent predictors of potentially suboptimal 
antibiotic treatment in multivariable analysis among CLC residents with an incident UTI. 






Fluoroquinolone exposure, 30 days prior to 
treatment 1.38 1.27 1.51 
Chronic renal disease  1.19 1.12 1.27 
Age*       
   > 85 years  1.17 1.07 1.29 
   75-84 years 1.07 0.98 1.17 
   65-74 years 0.99 0.91 1.08 
Prior skin or soft tissue infection 1.14 1.06 1.23 
Recent high WBC** 1.08 1.02 1.15 
Genitourinary disorder 1.08 1.02 1.15 
CLC= Community Living Center, UTI= Urinary tract infection; WBC= White Blood Cell Count 
 
We compared CLC residents with an incident UTI receiving potentially suboptimal antibiotic treatment and 
those receiving potentially optimal antibiotic treatment.  Potentially suboptimal antibiotic treatment was defined 
as exposure to any subtype of potentially suboptimal antibiotic treatment: drug choice (based on previous urine 
cultures and susceptibilities or local CLC urine antibiogram), dose frequency (based on renal function), and/or 
longer than recommended duration (greater than 14 days). 
 
The adjusted odds ratios are estimated from multivariable analysis of the data. The final multivariable 
unconditional logistic regression model included all predictive variables listed in the table above (odds ratio >1) 



















year prior, CLC urine culture in the year prior, outpatient urine culture in the year prior, cardiopulmonary 
disease comorbidity, hospitalization in the 30 days prior, and year. 
 
*Age compared to age < 65 years. 
 
**Recent high WBC was defined as a WBC > 10 x 103/μL within 7 days prior to treatment as compared to a 




















Figure 1. Flow chart for study population.  
 
CLC= Community Living Center, ICD-9/ICD-10= International Classification of Diseases, 9th or 10th Revision 
diagnosis codes, UTI= Urinary tract infection; VA=Veterans Affairs, y=Years 
 
*Other positive culture from another non-urine source (i.e. blood, respiratory, tissue, bone) during the UTI 
treatment period were excluded, unless it was a blood culture growing the same organism/s as in the urine. 
 
**Non-UTI antibiotics were defined as those not recommended by national treatment guidance and/or without 
reliable urine concentrations. Uncommon antibiotics were defined as those used in less than 10 residents.  
Non-UTI and uncommon antibiotics included the following: azithromycin, cefadroxil, cefotaxime, ceprozil, 
clarithromycin, colistemethate, dalbavancin, demeclocycline, erythromycin, fidaxomicin, methenamine, 
minocycline (used in less than 10 residents with Stenotrophomonas maltophilia and Acinetobacter spp.), 
moxifloxacin, oritavancin, penicillin, piperacillin, rifampin,streptomycin, telavancin, tetracycline, 
ticaracillin/clavulanate, and tigecycline (used in less than 10 residents with S. aureus, Klebsiella spp., E. coli, 
and Acinetobacter spp.).  For all residents except those with UTIs due to S. aureus and Enterococcus spp., 
non-UTI and rare included the following: daptomycin, linezolid, ceftaroline (S. aureus only), clindamycin (S. 
aureus only), oxacillin (S. aureus only), and nafcillin (S. aureus only). 
 
***We included only residents with an incident CLC UTI, defined as the first UTI identified during the study 
period with no previous UTIs treated in a CLC in the year prior.  Any other subsequent UTI identified in the 
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